An expert-led, CME-accredited program aiming to bridge the gaps in the multidisciplinary management of chronic kidney disease (CKD). It looks at improving early diagnosis and staging, and discusses strategies for more collaborative and coordinated care in the different global regions.
This program is suitable for nephrologists, endocrinologists, cardiologists, primary care and any other healthcare professionals who form the multidisciplinary team for CKD and its comorbidities.
Early identification of CKD through screening, followed by accurate diagnosis and staging to inform the best treatment, offers the potential to significantly reduce the morbidity and mortality of this burdensome disease and its complications. Our interactive eLearning will guide you through the steps to reach an early and accurate diagnosis, and when to refer, using evidence-based algorithms and classification systems.
This is now available in multiple languages: French, Spanish, German, Italian, Portuguese, Simplified Chinese and Japanese.
This eLearning activity has been endorsed by KDIGO and PCDE.
Chronic kidney disease (CKD) is increasingly understood to be a global health problem but is often under-recognized by both patients and clinicians. This program aims to highlight the burden and unmet needs within CKD identification and management. It looks at the challenges to effective multidisciplinary management of CKD, including achieving early diagnosis and avoiding progression, and discusses how newer antidiabetic agents can be used to improve patient outcomes.
David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients with chronic kidney disease.
Professor Wheeler’s other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. He has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.
David Wheeler discloses the following interests: Ongoing consultancy arrangement with AstraZeneca. Honoraria from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Napp, Mundipharma, and MSD.